Document is current
Any future updates will be listed below
-
Authors
Thomassin-Naggara, Isabelle https://orcid.org/0000-0002-0919-0133
Kilburn-Toppin, Fleur
Athanasiou, Alexandra
Forrai, Gabor
Ispas, Miruna
Lesaru, Mihai
Giannotti, Elisabetta
Pinker-Domenig, Katja
Van Ongeval, Chantal
Gilbert, Fiona
Mann, Ritse M.
Pediconi, Federica
,
Baltzer, Pascal
Herrero, Julia Camps
Clauser, Paola
Gilbert, Fiona J.
Fuchsjäger, Michael
Helbich, Thomas
Kuhl, Christiane K.
Fallenberg, Eva M.
Pijnappel, Rudd
Van Ongeval, Chantal
Sardanelli, Francesco
Sella, Tamar
Zackrisson, Sophia
- License Information
-
More Information
Article History
Received: 1 July 2024
Revised: 25 August 2024
Accepted: 1 September 2024
First Online: 15 November 2024
Compliance with ethical standards
:
: The scientific guarantor of this publication is Isabelle Thomassin-Naggara.
: The authors declare the following disclosures: <b>Isabelle Thomassin-Naggara</b>: <b>speakers bureaus</b>—European Society of Breast Imaging (active), Société d’imagerie de la femme (active), American College of Radiology O-RADS (active), Bayer (ended), Siemens Healthineers (ended), Guerbet (ended), Bard (ended); <b>Ponctual remunerated lectures:</b> GE, Siemens, Guerbet, Hologic, Canon, Guebet, Bracco, GSD, Samsung, Fujifilm, Incepto, ICAD; <b>Research grants:</b> ASCORDIA: ADNEX MR Scoring System: Impact of an MR scoring system on the therapeutic strategy of pelvic adnexal masses PHRC ID RCB 2015-A01593-46. <b>Katia Pinker-Domenig:</b><b>speakers bureaus</b>—European Society of Breast Imaging (active), Bayer (ended), Siemens Healthineers (ended), DKD 2019 (ended), Olea Medical (ended), Roche (ended), MedScape (ended). <b>Consulting</b>, <b>Advisory:</b><b>Consultant</b>—Genentech, Inc.: 05/19–present (non-monetary); <b>Consultant</b>—Merantix Healthcare: 05/20–1/2014; Consultant: AURA Health Technologies GmbH: 04/21–2/24; <b>Consultant</b>—Guerbet; 05/2023–1/2024; <b>Consultant</b>—Neodynamics: 12/20223–present. <b>Research grants:</b> Digital Hybrid Breast PET/MRI for Enhanced Diagnosis of Breast Cancer (HYPMED) H2020—Research and Innovation Framework Program PHC-11-2015 #667211-2, A Body Scan for Cancer Detection using Quantum Technology (CANCERSCAN) H2020-FETOPEN # 828978; Multiparametric 18F-Fluoroestradiol PET/MRI coupled with Radiomics Analysis and Machine Learning for Prediction and Assessment of Response to Neoadjuvant Endocrine Therapy in Patients with Hormone Receptor +/HER2 − Invasive Breast Cancer Jubiläumsfonds of the Austrian National Bank # Nr: 18207; Deciphering breast cancer heterogeneity and tackling the hypoxic tumor microenvironment challenge with PET/MRI, MSI and radiomics The Vienna Science and Technology Fund LS19-046; MSKCC 2020 Molecularly Targeted Intra-Operative Imaging Award 07/2020–06/2021, Breast Cancer Research Foundation 06/2019–05/2021; NIH R01 Breast Cancer Intravoxel-Incoherent-Motion MRI Multisite (BRIMM) 09/01/2020–08/30/2025 UG3 CA239861; NIH R01 subaward: Abbreviated Non-Contrast-Enhanced MRI for Breast Cancer Screening 09/01/2023–08/31/2025 R01 CA249893; NIH RO1: Deciphering the Acidic Tumor Environment: A Phase I/IIa Study of Pre-Operative Multiparametric MRI and pHLIP® ICG Intra-Operative Fluorescence Imaging of Primary Breast Cancer 03/01/2023–02/29/2024 1R01CA270018-01A1. Katja Pinker is supported in part through the NIH/NCI Cancer Center Support Grant P30 CA008748. All other authors have nothing to disclose directly related to the article.
: No complex statistical methods were necessary for this paper.
: Written informed consent was not required for this study.
: Institutional Review Board approval was not required.
: Not applicable.
:
